OpGen, Inc.

OPGN

US68373L5057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 27/06/2024 am IST			5-day change	1st Jan Change
2.57 ^USD	+0.39%		+1.58%	-38.81%

03/06	OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/05	OpGen, Inc. Announces Appointments to the Committees of the Board	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about OpGen, Inc.

OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/06	CI
OpGen, Inc. Announces Appointments to the Committees of the Board	31/05	CI
OpGen Gets Notice of Noncompliance From Nasdaq	24/04	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	26/03	MT
OpGen, Inc. Announces Management Changes	26/03	CI
OpGen, Inc. Announces Chief Executive Officer Changes	26/03	CI
OpGen, Inc. announced that it expects to receive $3 million in funding	25/03	CI
Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $699,022	15/11	MT
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
OpGen to Raise $1 Million From Private Placement Amid Talks For 'Potential Strategic' Deal	12/23/12	MT
OpGen, Inc. announced that it expects to receive $1 million in funding	11/23/11	CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/23/29	MT
Investors Await Inflation Data, Consumer Sentiment Report as US Futures Trend Higher Friday	29/23/29	MT
Top Premarket Gainers	29/23/29	MT
North American Morning Briefing : China Angst -2-	15/23/15	DJ
HC Wainwright Downgrades OpGen to Neutral From Buy	14/23/14	MT
Opgen Exploring Options	11/23/11	CI
OpGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Transcript : OpGen, Inc., Q2 2023 Earnings Call, Aug 10, 2023	11/23/11
Earnings Flash (OPGN) OPGEN Reports Q2 Revenue $736,136, vs. Street Est of $900,000	11/23/11	MT
Transcript : OpGen, Inc., Q1 2023 Earnings Call, May 15, 2023	16/23/16
Earnings Flash (OPGN) OPGEN Posts Q1 Revenue $0.91M	16/23/16	MT
OpGen, Inc. Provides Revenue Guidance for the Year 2023	16/23/16	CI
OpGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
US Stocks Set to Open Lower Amid Earnings Reports, Rising Personal Income	28/23/28	MT

OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
OPGEN, INC.	-38.81%	34.53L
MODERNA, INC.	+23.13%	4.69TCr
LONZA GROUP AG	+37.32%	3.91TCr
IQVIA HOLDINGS INC.	-8.73%	3.85TCr
ALNYLAM PHARMACEUTICALS, INC.	+28.09%	3.1TCr
CELLTRION, INC.	-12.26%	2.61TCr
ICON PUBLIC LIMITED COMPANY	+10.57%	2.59TCr
UNITED THERAPEUTICS CORPORATION	+45.05%	1.42TCr
MEDPACE HOLDINGS, INC.	+32.23%	1.25TCr
BIO-TECHNE CORPORATION	-6.56%	1.14TCr